fashion -WSS

fashion

author：leisure time 2025-09-28 02:47:30 - browse：5453

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Kenai launches with $82 million for Parkinson’s stem cell therapy

WSS

Cue Health's Covid

House looks to weaken Medicare negotiation

RSV vaccines may be linked to small increased risk of developing GBS

Key Senate committee drafts bipartisan bill to stem drug shortages

Orangutan used medicinal plant to treat wound, first time ever seen

Obesity now affects over 1 billion people worldwide, study finds

hotspot

fashion

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

Medical device lobby: We're tired of waiting on Medicare coverage

What does generative AI mean for health care? We asked experts

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Malaria cases in Florida and Texas: Here’s what you need to know

FDA does about

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Peter Hotez and the public health issue of online harassment

Flu vaccine offering decent levels of protection this winter, new data show

entertainment

Scientists unlock the key to scar

Medical device lobby: We're tired of waiting on Medicare coverage

Why does health care cost so much? A reading guide

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

FTC falls short on scrutinizing hospital mergers, study says

Obesity now affects over 1 billion people worldwide, study finds

focus

entertainment

focus

hotspot